Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Author(s): Raushan Kumar Chaudhary, Allen Pinto, Vineeth Mascarenhas, Ashwath Kampa Saliyan, Deepthi Avvaru, Anjana Babu and Uday Venkat Mateti*

DOI: 10.2174/0118756921339129240926055552

DownloadDownload PDF Flyer Cite As
Understanding Bacterial Roles in Cancer Chemo-resistance: A Signaling Pathway Mapping Study

Article ID: e18756921339129 Pages: 10

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Introduction: Chemoresistance is one of the leading causes of chemotherapy failure among cancer patients. Out of several hypotheses proposed for chemoresistance, bacteria-mediated chemoresistance to cancer drugs has not been well established. Thus, the aim of this review is to map the pathways by which bacteria exhibit chemoresistance in specific cancers.

Material and Methods: Relevant articles on bacteria-mediated chemoresistance in cancer were retrieved by conducting a systematic search across PubMed, Scopus and Web of Science databases. The search was limited to English original articles published until 15th December 2023.

Results: A total of nine articles were included to map the pathways involved in chemoresistance. Numerous pathways have been connected to various forms of cancer, such as autophagy pathway in colorectal and esophageal cancers by Fusobacterium nucleatum causing oxaliplatin and 5-FU resistance; DNA damage response pathway also by Fusobacterium nucleatum promoting CDDP resistance in esophageal cancer; Porphyromonas gingivalis led to oral and esophageal cancer resistance to paclitaxel via JAK/STAT pathway. NF-κB pathway involved in gastric cancer in the presence of Helicobacter pylori towards cisplatin, and also 5-FU resistance via the apoptotic pathway. Cellular metabolism modulation by Lactobacillus iners was also implicated in cervical cancer chemoresistance.

Conclusion: We conclude that bacteria can mediate chemoresistance not merely to antibiotics but also to anticancer drugs. Thus, a detailed understanding of the pathways associated with chemoresistance mediated via bacteria might help in targeting these pathways or antibiotics to prevent bacterial growth could help overcome resistance.

Keywords: Antineoplastic agents, bacteria, cancer, chemoresistance, signaling pathways, chemotherapy.

Graphical Abstract

[1]
Gilbertson RJ. Mapping cancer origins. Cell 2011; 145(1): 25-9.
[http://dx.doi.org/10.1016/j.cell.2011.03.019] [PMID: 21458665]
[2]
Cancer factsheets. 2024. Available from: https://gco.iarc.fr/today/en/fact-sheets-cancers (Accessed on: 15 February 2024)
[3]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[4]
Canadian Cancer Society. Available from: https://cancer.ca/en/cancer-information/what-is-cancer/types-of-cancer
[5]
Chaudhary RK, Khanal P, Mateti UV, Shastry CS, Shetty J. Identification of hub genes involved in cisplatin resistance in head and neck cancer. J Genet Eng Biotechnol 2023; 21(1): 9.
[http://dx.doi.org/10.1186/s43141-023-00468-y] [PMID: 36715825]
[6]
Al-Ouqaili MT. Depending on HPLC and PCR, detection of aflatoxin B1 extracted from Aspergillus flavus strains and it’ s cytotoxic effect on AFB treated-hematopoietic stem cells obtained from human umbilical cord. Asian J Pharm 2018; 12(03)
[7]
DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68(21): 8643-53.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6611] [PMID: 18974103]
[8]
Alam A, Farooq U, Singh R, et al. Chemotherapy treatment and strategy schemes: A review. Open Access J Toxicol 2018; 2(5): 555-600.
[http://dx.doi.org/10.19080/OAJT.2018.02.555600]
[9]
Lehouritis P, Cummins J, Stanton M, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep 2015; 5(1): 14554.
[http://dx.doi.org/10.1038/srep14554] [PMID: 26416623]
[10]
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2019; 2(2): 141-60.
[http://dx.doi.org/10.20517/cdr.2019.10] [PMID: 34322663]
[11]
Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. Science 2020; 368(6494): 973-80.
[http://dx.doi.org/10.1126/science.aay9189] [PMID: 32467386]
[12]
Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med 2019; 25(3): 377-88.
[http://dx.doi.org/10.1038/s41591-019-0377-7] [PMID: 30842679]
[13]
Livyatan I, Nejman D, Shental N, Straussman R. Characterization of the human tumor microbiome reveals tumor-type specific intra-cellular bacteria. OncoImmunology 2020; 9(1): 1800957.
[http://dx.doi.org/10.1080/2162402X.2020.1800957] [PMID: 32934891]
[14]
Al-Ouqaili MTS, Hussein RA, Majeed YH, Al-Marzooq F. Study of vacuolating cytotoxin A (vacA) genotypes of ulcerogenic and non-ulcerogenic strains of Helicobacter pylori and its association with gastric disease. Saudi J Biol Sci 2023; 30(12): 103867.
[http://dx.doi.org/10.1016/j.sjbs.2023.103867] [PMID: 38020230]
[15]
Garajová I, Balsano R, Wang H, et al. The role of the microbiome in drug resistance in gastrointestinal cancers. Expert Rev Anticancer Ther 2021; 21(2): 165-76.
[http://dx.doi.org/10.1080/14737140.2021.1844007] [PMID: 33115280]
[16]
Li X, Zhou Y, Li Y, et al. Autophagy: A novel mechanism of chemoresistance in cancers. Biomed Pharmacother 2019; 119: 109415.
[http://dx.doi.org/10.1016/j.biopha.2019.109415] [PMID: 31514065]
[17]
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017; 170(3): 548-563.e16.
[http://dx.doi.org/10.1016/j.cell.2017.07.008] [PMID: 28753429]
[18]
Liu Y, Baba Y, Ishimoto T, et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer 2021; 124(5): 963-74.
[http://dx.doi.org/10.1038/s41416-020-01198-5] [PMID: 33299132]
[19]
Zhang JW, Zhang D, Yin HS, et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway. Gut Microbes 2023; 15(1): 2197836.
[http://dx.doi.org/10.1080/19490976.2023.2197836] [PMID: 37017266]
[20]
Yusoh NA, Ahmad H, Gill MR. Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy. ChemMedChem 2020; 15(22): 2121-35.
[http://dx.doi.org/10.1002/cmdc.202000391] [PMID: 32812709]
[21]
Gao S, Liu Y, Duan X, et al. Porphyromonas gingivalis infection exacerbates oesophageal cancer and promotes resistance to neoadjuvant chemotherapy. Br J Cancer 2021; 125(3): 433-44.
[http://dx.doi.org/10.1038/s41416-021-01419-5] [PMID: 33981017]
[22]
Song JM, Woo BH, Lee JH, et al. Oral administration of Porphyromonas gingivalis, a major pathogen of chronic periodontitis, promotes resistance to paclitaxel in mouse xenografts of oral squamous cell carcinoma. Int J Mol Sci 2019; 20(10): 2494.
[http://dx.doi.org/10.3390/ijms20102494] [PMID: 31117164]
[23]
Shao L, Chen Z, Soutto M, et al. Helicobacter pylori ‐induced miR‐135b‐5p promotes cisplatin resistance in gastric cancer. FASEB J 2019; 33(1): 264-74.
[http://dx.doi.org/10.1096/fj.201701456RR] [PMID: 29985646]
[24]
Shirin H, Sordillo EM, Kolevska TK, et al. Chronic Helicobacter pylori infection induces an apoptosis-resistant phenotype associated with decreased expression of p27(kip1). Infect Immun 2000; 68(9): 5321-8.
[http://dx.doi.org/10.1128/IAI.68.9.5321-5328.2000] [PMID: 10948161]
[25]
Colbert LE, El Alam MB, Wang R, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell 2023; 41(11): 1945-1962.e11.
[http://dx.doi.org/10.1016/j.ccell.2023.09.012] [PMID: 37863066]
[26]
Zhang Y, Peng Q, Zheng J, et al. The function and mechanism of lactate and lactylation in tumor metabolism and microenvironment. Genes Dis 2023; 10(5): 2029-37.
[http://dx.doi.org/10.1016/j.gendis.2022.10.006] [PMID: 37492749]
[27]
Sayin S, Rosener B, Li CG, et al. Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells. eLife 2023; 12: e83140.
[http://dx.doi.org/10.7554/eLife.83140] [PMID: 36734518]